DEBT (Tables)

12 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

Long term debt as of September 30, 2024 and September 30, 2023 is detailed in the table below.

	September 30, 2024		September 30, 2023
Seller Note – Bolder BioPath (Related party)	$	376	$	602
Seller Note – Preclinical Research Services	464		541
Seller Payable - Orient BioResource Center	3,700		3,649
Seller Note – Histion (Related party)	84		229
Seller Note – Protypia (Related party)	—		400
Economic Injury Disaster Loan	—		140
Second Lien Notes	17,846		—
Convertible Senior Notes	109,979		110,651
Term Loan Facility, DDTL and Incremental Term Loans	272,840		272,930
Total debt before unamortized debt issuance costs	$	405,289	$	389,142
Less: Debt issuance costs not amortized	(11,950)		(11,397)
Total debt, net of unamortized debt issuance costs	$	393,339	$	377,745
Less: Current portion	(3,538)		(7,950)
Total Long-term debt	$	389,801	$	369,795

Below are the weighted-average effective interest rates for the loans available under the Credit Agreement:

	Twelve Months Ended September 30,
	2024		2023
Effective interest rates:
Term Loan	11.39	%	10.41	%
Initial DDTL	11.37	%	10.41	%
Additional DDTL	11.50	%	10.57	%

Schedule of Maturities of Long-Term Debt

The following table summarizes the amount of maturities of our total debt for each of the next five fiscal years and thereafter:

	2025		2026		2027		2028		2029		Thereafter		Total
Debt	$	3,538	$	6,614	$	285,158	$	109,979	$	—	$	—	$	405,289